Abstract:The pandemic of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is now sweeping the globe like the toppling Dominoes, and has become an alarming public health issue worldwide. To date, there have been more than 76 million confirmed cases and more than 1,690,000 deaths worldwide. SARS-CoV-2 might originate from bats and is usually transmitted through respiratory droplets and contact. The SARS-CoV-2 genome is about 30 kilobases in length, encoding 16 non-structural proteins and 4 structural proteins. The receptor-binding domain (RBD) in the S1 subunit of the spike (S) protein of SARS-CoV-2 interacts with the entry receptor angiotensin-converting enzyme 2 (ACE2) on host alveolar type II epithelial cells. The interaction causes structural changes in the S2 subunit leading to virus-host cell fusion. RNA-dependent RNA polymerase (RdRp) is vital to replication of the viral genome. ACE2 may be downregulated after infection, leading to lung edema and injury. Common symptoms of SARS-CoV-2 infection include fever, dry cough, dyspnea, fatigue, and myalgia, that is, a pneumonia that has been termed coronavirus disease-2019 (COVID-19) by the World Health Organization. COVID-19 can be fatal. The imaging findings of the lung are mostly multiple ground glass shadows and subsegmental consolidation near the pleura. SARS-CoV-2 can be detected by nucleic acid and antibody tests, virus isolation, and electron microscopy. The pathological features of COVID-19 are diffuse alveolar injury, fibrous myxoid exudate, interstitial inflammation, alveolar epithelial cell proliferation and shedding, and hyaline membrane formation. At present, antivirals are non-specific and mainly include lopinavir/ritonavir, remdesivir, and umifenovir. EK1 peptide and SARS-CoV-2-HR2P may be novel antiviral agents that can prevent infection. Convalescent plasma is generally a valid option. Although no vaccine is officially available, there are inactivated vaccines, vectored vaccines and nucleic acid-based vaccines in clinical trials. Prompt and strong measures have been taken to prevent the transmission of SARS-CoV-2 in China.

Potential Pathogenesis of Severe Acute Respiratory Syndrome Coronavirus 2.

Role of angiotensin-converting enzyme 2 (ACE2) in COVID-19

Severe Acute Respiratory Syndrome Coronavirus 2: from Gene Structure to Pathogenic Mechanisms and Potential Therapy.

Exploring the pathogenesis of severe acute respiratory syndrome (SARS): the tissue distribution of the coronavirus (SARS-CoV) and its putative receptor, angiotensin-converting enzyme 2 (ACE2)

The Pathogenic Features of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2): Possible Mechanisms for Immune Evasion?

Severe acute respiratory syndrome coronavirus 2 for physicians: Molecular characteristics and host immunity (Review).

Recombinant Human ACE2: Potential Therapeutics of SARS-CoV-2 Infection and Its Complication

Role of Endolysosomes in Severe Acute Respiratory Syndrome Coronavirus-2 Infection and Coronavirus Disease 2019 Pathogenesis: Implications for Potential Treatments

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): An overview of viral structure and host response

Increasing Host Cellular Receptor—Angiotensin-Converting Enzyme 2 (ACE2) Expression by Coronavirus May Facilitate 2019-Ncov Infection

ACE2, B0AT1, and SARS-CoV-2 spike protein: Structural and functional implications.

Potential use of the S-protein–Angiotensin converting enzyme 2 binding pathway in the treatment of coronavirus disease 2019

The Two-Way Switch Role of ACE2 in the Treatment of Novel Coronavirus Pneumonia and Underlying Comorbidities

A novel coronavirus&mdash;from basic research to clinic

A comparative review of pathogenesis and host innate immunity evasion strategies among the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), severe acute respiratory syndrome coronavirus (SARS-CoV) and the Middle East respiratory syndrome coronavirus (MERS-CoV)

SARS-CoV-2 E Protein: Pathogenesis and Potential Therapeutic Development

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges

Severe Acute Respiratory Syndrome Coronavirus 2 and Coronavirus Disease 2019

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): a review

Epidemiology, virology, and clinical features of severe acute respiratory syndrome -coronavirus-2 (SARS-CoV-2; Coronavirus Disease-19)

SARS-CoV-2: pathogenesis, therapeutics, variants, and vaccines